These are good times for investors to start thinking about putting
together shopping lists for speculative healthcare stocks, as the market
has been bailing out on not only biotechs but also speculative
med-techs. AtriCure (ATRC)
isn't speculative in many important respects, as the company has
approvals for its key products, but is still quite speculative insofar
as the company's ability to convince doctors to adopt its surgical
ablation approach and generate meaningful revenue and profits.
Read more here:
AtriCure Making Progress, But Can It Maximize Value On Its Own?
No comments:
Post a Comment